Dr Fraser Murray is an experienced drug hunter and entrepreneur with almost 30 years of experience in drug discovery and early development in both pharma and biotech.
In addition to being Head of Scientific Evaluation at Advent Life Sciences he is also CEO of Advent portfolio company Pheno Therapeutics. He was most recently Chief Executive Officer of Pandeia Therapeutics which was acquired by a mid-cap pharmaceutical company in December 2022.
Prior to this he was Chief Scientific Officer of Chronos Therapeutics and Chief Executive Officer of Polleo Pharma. Fraser has co-founded 5 biotech companies and consulted for multiple startups and venture capital firms since leaving a career in big pharma. Fraser began his career as a scientist at Merck’s Neuroscience Research Centre in the UK before moving on to roles at Astra Zeneca and Shire where he headed discovery biology for Speciality Pharmaceuticals. Fraser studied Immunology and Pharmacology at the University of Strathclyde and undertook a PhD in Neuropharmacology at the School of Pharmacy, University of London. He later studied for an executive MBA at Alliance Manchester Business School.
We use our own and third party cookies that are essential to make our website work. We also use other cookies for analytics on site usage to help us improve our site and give you an easy and personalised experience. You can 'Accept All' other cookies or customise your preferences to reject or permit specific cookies by visiting "Cookie Consent" and selecting "Cookie Settings" in the pop-up at the bottom of the window.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.